The Danish Medicines Agency (DKMA) has released a standardized Investigator’s Brochure (IB) template specifically designed for cell therapy products, according to an announcement published on the agency’s official website. The template is now publicly available and intended to streamline regulatory documentation for researchers planning clinical trials in advanced therapy medicinal products (ATMPs).
Key takeaways
- The Danish Medicines Agency has published a dedicated IB template for cell therapy clinical trial applications
- The template is designed to standardize documentation for advanced therapy medicinal products (ATMPs)
- Availability of the template may reduce administrative burden and improve trial submission quality across Nordic and European researchers
Standardizing cell therapy documentation
Clinical trials for cell-based therapies require comprehensive safety and manufacturing documentation that differs substantially from traditional pharmaceutical products. The DKMA’s new template provides a structured framework that aligns with European Medicines Agency (EMA) guidelines for ATMP development, helping research teams prepare compliant Investigator’s Brochures without starting from blank documents.
The Investigator’s Brochure is a critical regulatory document that summarizes all available preclinical and clinical data on an investigational product. For cell therapies—which involve living cells, genetic modifications, or tissue engineering—the IB must address unique considerations including cell sourcing, manufacturing consistency, viability assays, and long-term follow-up protocols. Standardized templates reduce inconsistencies across trial applications and accelerate regulatory review timelines.
Cell therapy trial documentation requirements
Key elements typically included in regulatory Investigator’s Brochures
Source: EMA ATMP Guidelines | Danish Medicines Agency, 2026 | Georgian Medical Journal News
Regulatory context for advanced therapy medicinal products
The European Medicines Agency (EMA) has established rigorous standards for ATMPs to ensure patient safety while facilitating innovation in regenerative medicine, gene therapy, and somatic cell therapies. Within this framework, national competent authorities like the DKMA play a crucial role in supporting early-phase trial development and providing pre-clinical consultation to sponsors. The availability of a harmonized IB template strengthens this support infrastructure across European jurisdictions.
Cell therapies present distinct regulatory challenges compared to conventional drugs: manufacturing variability, donor-dependent biological properties, and the need for long-term immunogenicity monitoring. By providing a detailed, disease-indication-agnostic template aligned with EMA requirements, the DKMA reduces trial sponsors’ uncertainty about documentation standards and lowers the likelihood of regulatory requests for additional information during review cycles.
Implications for Nordic and European researchers
The template release supports quality and consistency in cell therapy trial documentation across the Nordic region and may serve as a model for other national medicines agencies. Research teams at academic institutions, biotech firms, and clinical centers can now access a DKMA-endorsed format that reflects current regulatory best practice, reducing time spent on document structure and permitting focus on substantive scientific content. This is particularly valuable for smaller research organizations lacking dedicated regulatory affairs personnel.
The Danish Medicines Agency’s release of a standardized Investigator’s Brochure template for cell therapy products represents a proactive step to harmonize regulatory documentation requirements for advanced therapy medicinal products and accelerate clinical trial development in Nordic and European research institutions.
— Danish Medicines Agency, 2026
What this means
Frequently asked questions
What is an Investigator’s Brochure and why is it required?
An Investigator’s Brochure (IB) is a comprehensive regulatory document that summarizes all available preclinical, pharmacology, toxicology, and clinical data on an investigational product. The EMA requires an IB before initiating clinical trials to ensure that investigators and ethics committees have sufficient information to evaluate risk-benefit ratios and make informed decisions about trial safety.
How does the DKMA template differ from generic IB formats?
The DKMA template is specifically tailored to cell therapy products, addressing unique documentation requirements such as manufacturing consistency of living cell products, donor variability, immunogenicity monitoring protocols, and long-term safety follow-up—elements that differ substantially from traditional pharmaceutical drug applications.
Is the template mandatory or optional for clinical trials in Denmark?
While the DKMA provides the template as a best-practice resource aligned with EMA guidance, actual requirements depend on the regulatory pathway (national approval, EMA centralized procedure, or expanded access). Researchers should contact the DKMA early in trial planning to confirm which documentation format aligns with their specific trial classification and jurisdiction.
The release of this template reflects broader regulatory modernization within European medicines agencies to support innovation while maintaining safety standards. As cell therapy research continues to accelerate across academic and commercial sectors, standardized documentation frameworks are likely to become increasingly important in reducing bottlenecks and enabling more efficient translation of laboratory findings into clinical applications. Researchers planning ATMP trials are encouraged to consult the publicly available template and engage with the DKMA’s regulatory support services during trial design.
Source: Danish Medicines Agency, “Are you working with cell therapy and planning a clinical trial?” 2026
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
